Influenza virus vaccine quadrivalent - SK Bioscience

Drug Profile

Influenza virus vaccine quadrivalent - SK Bioscience

Alternative Names: Cell culture derived quadrivalent inactivated subunit influenza vaccine - SK Bioscience; NBP 607-QIV; NBP 607-quadrivalent; Quadrivalent inactivated cell culture derived influenza vaccine - SK Bioscience; Sky Cell Flu; SKYCellflu quadrivalent

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK Chemicals
  • Developer SK Bioscience
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 02 Jul 2018 SK Chemicals divested the vaccine business portfolio to a newly formed subsidiary SK Bioscience
  • 01 Jun 2017 SK Chemicals completes a phase III trial in Influenza virus infections (Prevention, In infants, In children) in South Korea (NCT03020628)
  • 26 Oct 2016 Adverse events and immunogenicity data from a phase III trial in Influenza virus infections presented at the IDWeek 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top